Bank Of New York Mellon Corp Ultragenyx Pharmaceutical Inc. Transaction History

Bank Of New York Mellon Corp

$538 Trillion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $22 Million - $30.2 Million	651,744 New	651,744 $30.2 Million
Q3 2022 Nov 14, 2022	SELL	$39.96 - $66.14 $2.33 Million - $3.86 Million	-58,322 Reduced 7.35%	735,710 $30.5 Million
Q2 2022 Aug 15, 2022	BUY	$45.8 - $85.4 $1.79 Million - $3.33 Million	39,000 Added 5.17%	794,032 $47.4 Million
Q1 2022 May 11, 2022	SELL	$62.2 - $84.4 $5.88 Million - $7.98 Million	-94,511 Reduced 11.12%	755,032 $54.8 Million
Q4 2021 Feb 11, 2022	SELL	$73.71 - $87.86 $1.09 Million - $1.3 Million	-14,802 Reduced 1.71%	849,543 $71.4 Million
Q3 2021 Nov 12, 2021	BUY	$77.92 - $102.4 $349,704 - $459,571	4,488 Added 0.52%	864,345 $78 Million
Q2 2021 Aug 11, 2021	BUY	$92.19 - $115.71 $3.5 Million - $4.39 Million	37,942 Added 4.62%	859,857 $82 Million
Q1 2021 May 13, 2021	BUY	$106.9 - $167.73 $6.76 Million - $10.6 Million	63,283 Added 8.34%	821,915 $93.6 Million
Q4 2020 Feb 09, 2021	SELL	$84.4 - $177.39 $1.16 Million - $2.44 Million	-13,757 Reduced 1.78%	758,632 $105 Million
Q3 2020 Nov 12, 2020	BUY	$72.98 - $90.0 $1.26 Million - $1.55 Million	17,240 Added 2.28%	772,389 $63.5 Million
Q2 2020 Aug 12, 2020	BUY	$46.91 - $78.22 $2.38 Million - $3.97 Million	50,733 Added 7.2%	755,149 $59.1 Million
Q1 2020 May 06, 2020	BUY	$33.8 - $62.9 $16 Million - $29.8 Million	473,598 Added 205.18%	704,416 $31.3 Million
Q4 2019 Feb 14, 2020	BUY	$36.08 - $45.83 $164,957 - $209,534	4,572 Added 2.02%	230,818 $9.86 Million
Q3 2019 Nov 07, 2019	SELL	$42.5 - $63.11 $83,300 - $123,695	-1,960 Reduced 0.86%	226,246 $9.68 Million
Q2 2019 Aug 12, 2019	SELL	$54.93 - $74.36 $26,805 - $36,287	-488 Reduced 0.21%	228,206 $14.5 Million
Q1 2019 May 14, 2019	BUY	$39.87 - $69.36 $828,020 - $1.44 Million	20,768 Added 9.99%	228,694 $15.9 Million
Q4 2018 Feb 11, 2019	BUY	$38.89 - $77.3 $25,706 - $51,095	661 Added 0.32%	207,926 $9.04 Million
Q3 2018 Nov 09, 2018	SELL	$71.81 - $90.15 $28,508 - $35,789	-397 Reduced 0.19%	207,265 $0
Q2 2018 Aug 06, 2018	BUY	$48.54 - $85.31 $189,451 - $332,964	3,903 Added 1.92%	207,662 $16 Million
Q1 2018 May 15, 2018	BUY	$44.33 - $58.52 $1.25 Million - $1.65 Million	28,142 Added 16.02%	203,759 $10.4 Million
Q4 2017 Feb 09, 2018	BUY	$43.54 - $57.32 $7.65 Million - $10.1 Million	175,617	175,617 $8.15 Million

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

Vanguard Group Inc Valley Forge, PA

9.95M
Shares

$445 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.6M
Shares

$251 Million
0.01% of portfolio
Sands Capital Management, LLC Arlington, VA

5.12M
Shares

$229 Million
0.91% of portfolio
Wellington Management Group LLP Boston, MA

4.17M
Shares

$186 Million
0.04% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.07M
Shares

$137 Million
0.02% of portfolio

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.13B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account